FR104/VEL-101 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

15,561 results for “FR104/VEL-101”

Trials

View all 8074 →

VEL-101 to Prevent Rejection After Kidney Transplantation

120 participants · First posted Dec 18, 2025

A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101

60 participants · First posted Feb 14, 2022

Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104

64 participants · First posted Jun 15, 2016

Drugs

View all 5347 →

VEL-0230

FR-104

VAL-101

Organizations

View all 108 →

浙江章光101有限公司

EUN JUNG KIM

United States

北京章光101药业有限公司

News

View all 2032 →

OSE Immunotherapeutics Announces Positive H1 2024 Results and Corporate Updates

OSE Immunotherapeutics Reports Strong Financial Results and Pipeline Progress in 2024

Veloxis Pharmaceuticals' Transplant Candidate VEL-101 Receives Official Name "Pegrizeprument"

Page 1 of 1557